// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity

Alvar Agusti - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

The Leicester Cough Questionnaire in two phase 3 trials of gefapixant in chronic cough

Surinder S. Birring - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

Neurally adjusted ventilatory assist (NAVA) in very preterm infants: A single tertiary neonatal unit’s experience

Sandeep Shetty - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Feasibility of assessing ventilation inhomogeneity by volumetric capnography during resuscitation of preterm infants

Emma Williams - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prediction of infant extubation success using the diaphragmatic electromyography (EMG) signal during a spontaneous breathing test (SBT)

Fahad Muhamed Shareef Arattu Thodika - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Long term lung function in those born of multiple versus singleton pregnancies

Christopher Harris - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Influence of antenatal corticosteroids and sex on the mortality and morbidity of extremelyprematurely born infants

Rebecca Lee - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Less invasive surfactant administration (LISA) to preterm infants on high flow nasal cannula (nHFT)

Asad Nasim - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

MDT010

In what ways are a long term ventilation service able to support the care of adults with learning disability?

Deirdre Mccourt - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictors of the need for NIV during percutaneous endoscopic gastrostomy insertion in patients with MND

Hussain Ebrahim - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Retrospective Review of Advanced Respiratory Support for COVID-19 Associated ARDS in a Ward-Based Setting

Fraser Easton - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Acute lung injury

N/A

Outcomes in patients requiring CPAP for COVID-19 infection in non-ITU settings

Benjamin Pippard - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Predictors of mortality in COVID-19 patients requiring CPAP

Muhammad Shafiq - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Severe COVID-19 pneumonia

N/A

Predictors of continuous positive airway pressure (CPAP) response in severe hypoxaemic respiratory failure due to COVID-19 pneumonitis

Jonathon Shaw - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary alveolar proteinosis

N/A

Outcomes and characteristics of COVID-19 patients treated with CPAP/ HFNO outside of the Intensive Care setting

Dominic L Sykes - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Cost-effectiveness of the use of Continuous Positive Airway Pressure in COVID-19 patients at Medway NHS Foundation Trust

Thomas Gower - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

How far is too far? A review of non-invasive ventilation as ceiling of care in COVID-19 patients not suitable for invasive mechanical ventilation

Elizabeth Springate - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

CPAP as a useful tool in COVID-19 related acute hypoxemic respiratory failure: Experience from 3 UKhospitals

Yasser Ahmed - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

The impact of embedding trial recruitment into a clinical care pathway

Kay Por Yip - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Non-Invasive Respiratory Support outcomes in patients with SARS-Cov-2 and Respiratory Failure managed in an Acute Respiratory Care Unit (ARCU)

Milan Barik - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved